Core Insights - InSilicoMedicine has submitted an application for listing on the Hong Kong Stock Exchange, aiming to leverage its AI-driven biotechnology platform Pharma.AI, which has generated over 20 clinical or IND-stage assets [1] Group 1: AI-Driven Drug Development - InSilicoMedicine, established in 2014, focuses on AI-driven drug development, utilizing its Pharma.AI platform composed of four modules: Biology42, Chemistry42, Medicine42, and Science42, providing end-to-end services from target identification to clinical outcome prediction [1] - The company has significantly improved drug development efficiency, exemplified by the new TNIK target, which took only 18 months from discovery to the first human clinical trial, compared to the traditional average of 4.5 years [1] - Multiple candidate drugs are currently in clinical stages, including ISM001-055, which has completed Phase IIa trials in China and received FDA orphan drug designation, and ISM3091, which has initiated Phase I trials in the U.S. [1] Group 2: Major Licensing Agreements - InSilicoMedicine has successfully licensed three candidate drugs to international pharmaceutical companies, with total contract values exceeding $2 billion [2] - In September 2023, ISM3091 was licensed to Exelixis for a total value of up to $875 million, including an $80 million upfront payment [2] - In December 2023, ISM5043 was licensed to Stemline for a total value of up to $506 million, with a $12 million upfront payment, and another agreement for an AI-based preclinical asset for solid tumors was made in December 2024, valued at over $550 million [2] Group 3: Revenue Growth and Diversification - InSilicoMedicine has established a diversified business model, including drug discovery and pipeline development, software solutions, and other discoveries, with revenue growing from $30.15 million in 2022 to $85.83 million in 2024 [3] - Over 90% of the revenue comes from drug discovery and pipeline development, primarily through strategic collaborations with companies like Fosun Pharma and Sanofi [3] - The company is expanding its AI technology into non-pharmaceutical sectors such as advanced materials, agriculture, nutrition products, and veterinary medicine [3]